theMednetRegister
  • Community
    • Overview
    • Experts
    • Editors
    • Fellows
    • Code of conduct
    • AI Guidelines for Physicians
  • Company
    • About Us
    • FAQs
    • Privacy Policy
    • Terms of Use
    • Careers
    • Programs
  • News
    • News Releases
    • Press Coverage
    • Publications
    • Blog
  • Contact Us
  • Sign in

General Internal Medicine

Bone health   

Questions discussed in this category


What is the optimal management of pain and loss of function due to pathologic compression fractures?
Assume no epidural/cord compromise. Is kypho/vertebroplasty, radiation therapy, or conservative management (brace, antiresorptive therapy) the superio...
1 Answer available

Are there any concerns regarding side effects in changing from denosumab to zolendronic acid or vice versa?
1 Answer available

Do you recommend medical therapy for extensive atraumatic osteonecrosis of the femoral head to mitigate pain or prevent femoral head collapse?
1 Answer available
22404158688518


Papers discussed in this category


Cancer Chemother Pharmacol, 2021 Mar 31
Switching from zoledronic acid to denosumab increases the risk for developing medication-related osteonecrosis of the jaw in patients with bone metastases.

J Bone Miner Metab, 2020 Jul 12
Zoledronic acid sequential therapy could avoid disadvantages due to the discontinuation of less than 3-year denosumab treatment.

Related Topics in General Internal Medicine

  • Lung Cancer
  • Breast Cancer
  • Head and Neck Cancers
  • Hematologic Malignancies
  • Radiation Oncology
  • Gynecologic Oncology
  • Palliation
  • Neuro-Oncology
  • Gastrointestinal Cancers
  • Genitourinary Cancers

Copyright © 2025 theMednet
All Rights Reserved.